businessbriefs
10:33in productionCh. 1 · Papain, not platforms/ 10:33 · ceiling 15 min
Startups & venture

Biocon

Kiran Mazumdar-Shaw · 1978

Biocon succeeded not by disrupting pharma—but by exploiting India’s foreign ownership rules to build a self-funded, export-first biotech that never needed venture capital.

Biocon is a rare case of a biotech company built without VC, without US incorporation, and without founder exit—its growth was constrained and enabled by Indian law, not Silicon Valley logic.

Startups & ventureIndiaBiographySupply chainsIndia across the network →
Chapters & takeaways5
  1. 1:05
    Papain, not platforms

    Biocon began with $10,000 and papain—not software or science fiction.

  2. 2:22
    First out of the gate

    Exporting enzymes to the US and Europe in 1979 was its first real market test—and its first regulatory win.

  3. 4:06
    70% by law

    Indian foreign investment law gave Kiran Mazumdar-Shaw 70% ownership from day one—no dilution, no boardroom battles.

  4. 5:12
    Cuba, not California

    The 1990 Cuba joint venture was Biocon’s first step into biologics—not a pivot, but a controlled extension of enzyme expertise.

  5. 6:25
    Three revenue streams, one constraint

    Its revenue model remains split: APIs sold globally at commodity margins, biosimilars sold in bulk to emerging markets, and branded formulations sold domestically under price pressure.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • export-first-enzyme-manufacturing-built-credibility
  • 70-percent-founder-ownership-enabled-long-term-control
  • cuba-joint-venture-was-a-low-risk-biologics-entry
What does not
  • biocon-does-not-control-us-eu-commercial-infrastructure
  • biocon-does-not-have-domestic-pricing-leverage
Study it if
  • students-of-indian-regulatory-arbitrage
  • researchers-of-emerging-market-biotech-scaling
Skip it if
  • investors-seeking-growth-metrics
  • founders-looking-for-vc-playbooks
The written brief1 min read

What the company or idea is

Biocon is an Indian biopharmaceutical company founded in 1978 in Bengaluru as a brewing enzyme producer, later evolving into a vertically integrated developer and manufacturer of APIs, biosimilars, and branded drugs.

How it actually makes money

Biocon makes money by manufacturing and exporting generic active pharmaceutical ingredients (APIs) to ~120 countries, selling branded formulations in India for metabolics, oncology, immunotherapy, and nephrology, and selling biosimilars in bulk and formulation form across emerging markets.

What works

Its early focus on export-grade enzyme manufacturing created technical credibility and regulatory access. That credibility enabled entry into US and EU markets before Indian peers—and sustained it through the 1990 joint venture with Cuba’s Center of Molecular Immunology and the 2000s launch of Biocon Biologics.

What does not

Biocon does not control its own US or European commercial infrastructure. It relies on partnerships to sell biosimilars there, and its Indian formulations face price controls and fragmented distribution.

What to take from it

Biocon demonstrates how regulatory constraints—like the 30% foreign ownership cap—can entrench founder control while forcing organic vertical integration: from papain extraction to FDA-approved biosimilars, all without external equity dilution.

Is it worth your time

Yes—if you are studying how Indian biotech navigated foreign ownership limits, built export capacity from enzyme extraction, or scaled biosimilars without domestic pricing leverage.

Same desk · Startups & venture4 of 52
12:42
Google DeepMindDemis Hassabis · 2010Google DeepMind is a research lab, not a business. Its value lies in its ability to produce peer-recognised scientific milestones — not revenue, not IP licensing, not product deployment. It proves that one company can fund high-risk, long-horizon AI research at industrial scale — but only by insulating it entirely from market logic.
8:28
GoogleLarry Page & Sergey Brin · 1998Google is a search engine company founded in 1998 by Larry Page and Sergey Brin. Its core technology, PageRank, ranked websites by inbound links — a method co-published with Motwani and Winograd and patented by Stanford. Scott Hassan wrote the first implementation. The company launched from Susan Wojcicki’s garage. Its name misspelled 'googol' to signal scale. Initial funding came from Andy Bechtolsheim’s $100,000 cheque in August 1998. The sources say nothing about advertising, revenue, users, infrastructure costs, or market position beyond this.
9:14
Jack DorseyJack Dorsey founded Twitter in 2007 after conceiving a real-time status service in 2000. He led its early development with explicit design principles—simplicity, constraint, craftsmanship—and prioritised technical reliability (uptime) over monetisation. Twitter had no revenue model as of 2008. Dorsey identified commercial use and API access as future paths to paid features, but neither yielded income during his first tenure. He secured two rounds of venture capital while deferring all revenue decisions.
10:02
Peter ThielThiel is a founder who treats money, data, and education as broken systems—and replaces them with proprietary alternatives. His ventures share a method: early, decisive capital deployment to technically rigorous teams. But his stated mission—to escape currency devaluation—contradicts the dollar-based economics of every exit, investment, and contract he has overseen.
Up next in Business

Bonduelle

1853 · 11:17

Bonduelle didn’t build a vegetable empire—it built a preservation empire, one can, freezer, and salad kit at a time.

Play nextBack to Startups & venture
11:17